National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 8 of 10
Leptin to Treat Lipodystrophy
NCT00025883
Motivations for Weight Loss
NCT00011115
Genetic Analysis of Familial Keloids
NCT00008502
Lamivudine and Adefovir to Treat Chronic Hepatitis B
NCT00023309
Pegylated Interferon to Treat Chronic Hepatitis D
NCT00023322
Diabetes Therapy to Improve BMI and Lung Function in CF
NCT00072904
Prevention of Recurrent Hepatitis B After Liver Transplantation
NCT00059267
Treatment of Nonalcoholic Steatohepatitis With Pioglitazone
NCT00013598
Prevention of Weight Gain
NCT00011102
Kidney Transplant for HIV-Infected Patients in Renal Failure
NCT00009009
Permeability Factor in Focal Segmental Glomerulosclerosis
NCT00007475
Solitary Islet Transplantation for Type 1 Diabetes Mellitus Using Steroid Sparing Immunosuppression
NCT00006505
Gabapentin to Treat Itch in Patients With Liver Disease
NCT00058890
A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy
NCT00006190
Randomized Trial of Health Events Costs in Diabetic Blacks
NCT00022750
Immune Response to Hepatitis C Virus
NCT00006301
Oxidative Stress and Vitamin E Requirements
NCT00067899
Vitamin K and Bone Turnover in Postmenopausal Women
NCT00062595
The Use of the Internet to Facilitate Weight Loss and Maintenance.
NCT00008827
Differential Metabolism of Dietary Fatty Acids
NCT00059254
Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection
NCT00006178
Islet Cell Transplantation Alone in Patients With Type I Diabetes Mellitus: Steroid-free Immunosuppression
NCT00021788
Search for New Methods to Detect Acute Renal Failure
NCT00026702
Evaluation of New Test Method to Measure Kidney Function
NCT00026715
Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
NCT00006164
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
NCT00005910
5-Azacytidine and Phenylbutyrate to Treat Severe Thalassemia
NCT00005934
Leptin to Treat Lipodystrophy
NCT00005905
Genetics of Hepatitis C Virus Infection
NCT00005657
Altered Calcium and Vitamin D in PMDD or Severe PMS
NCT00005119
NEW DAY: Nutrition, Exercise, Weight Loss, Diabetes And You
NCT00007800
Physical Activity in the Treatment of Obesity
NCT00615238
Energy Homeostasis in Anorexia Nervosa
NCT00368667
Islet Cell Transplantation Alone and CD34+ Enriched Bone Marrow Cell Infusion in Patients With Diabetes Mellitus: Steroid-Free Regimen
NCT00021801
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
NCT00004990
A Phase I/II Trial of Recombinant-Methionyl Human Stem Cell Factor (SCF) in Adult Patients With Sickling Disorders
NCT00005783
A Study of the Safety and Efficacy of Tobramycin for Inhalation in Young Children With Cystic Fibrosis
NCT00006280
Food Intake and Appetite in the Children of Mothers With Diabetes
NCT00339313
Glomerular Injury of Preeclampsia
NCT00275158
Evaluating "Health at Every Size"(HAES) as an Alternative Obesity Treatment Model
NCT00074633
Mobilization and Handling of Stem Cells for Transplant From Healthy Volunteers With Sickle Cell Trait
NCT00005782
Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus
NCT00001985
Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
NCT00001958
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
NCT00001959
The Food Intake Phenotype: Assessing Eating Behavior and Food Preferences as Risk Factors for Obesity
NCT00342732
Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
NCT00001984
The Family Investigation of Nephropathy and Diabetes Study
NCT00301249
Education and Group Support for Diabetic Hispanics
NCT00004983
Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer
NCT00005785
Biofeedback for Dyssynergic Constipation
NCT00127257
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.